• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Insiders Buying Asana And 2 Other Stocks

    7/13/23 7:39:17 AM ET
    $ASAN
    $JEQ
    $NVCT
    Computer Software: Prepackaged Software
    Technology
    Air Freight/Delivery Services
    Consumer Discretionary
    Get the next $ASAN alert in real time by email

    When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

    Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

    Asana

    • The Trade: Asana, Inc. (NYSE:ASAN) President, CEO and Chairman Dustin Moskovitz acquired a total of 160,000 shares an average price of $21.72. To acquire these shares, it cost around $3.47 million.
    • What’s Happening: Asana reported better-than-expected first-quarter financial results and issued FY24 EPS guidance above estimates.
    • What Asana Does: Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives.

    Nuvectis Pharma

    • The Trade: Nuvectis Pharma, Inc. (NASDAQ:NVCT) 10% owner Charles Mosseri-Marlio acquired a total of 10,000 shares at an average price of $15.36. To acquire these shares, it cost around $153,600.
    • What’s Happening: Nuvectis Pharma recently announced FDA clearance of NXP900 IND.
    • What Nuvectis Pharma Does: Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology.

    Don’t forget to check out our premarket coverage here

    Aberdeen Japan Equity Fund

    • The Trade: Aberdeen Japan Equity Fund Inc (NYSE:JEQ) Director Bill Maher bought a total of 1,500 shares at an average price of $5.84. To acquire these shares, it cost around $8,760.
    • What’s Happening: abrdn Japan Equity Fund recently appointed William Maher to the Board of Directors of the Fund as a Class III Director.
    • What Abrdn Japan Equity Fund Does: Aberdeen Japan Equity Fund Inc is a United States-based closed-end diversified management investment company.

     

    Check This Out: Investor Sentiment Improves Following Inflation Report

    Get the next $ASAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASAN
    $JEQ
    $NVCT

    CompanyDatePrice TargetRatingAnalyst
    Asana Inc.
    $ASAN
    1/15/2026$16.00Neutral → Buy
    Citigroup
    Asana Inc.
    $ASAN
    12/17/2025Neutral
    BTIG Research
    Asana Inc.
    $ASAN
    12/15/2025$18.00Sector Weight → Overweight
    KeyBanc Capital Markets
    Asana Inc.
    $ASAN
    6/4/2025$13.00 → $10.00Hold → Reduce
    HSBC Securities
    Asana Inc.
    $ASAN
    5/20/2025$14.00Equal-Weight → Underweight
    Morgan Stanley
    Nuvectis Pharma Inc.
    $NVCT
    4/2/2025$17.00Buy
    Maxim Group
    Nuvectis Pharma Inc.
    $NVCT
    3/17/2025$19.00Buy
    Laidlaw
    Asana Inc.
    $ASAN
    12/6/2024Underweight → Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $ASAN
    $JEQ
    $NVCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cohler Matt was granted 823 shares, increasing direct ownership by 0.24% to 339,849 units (SEC Form 4)

    4 - Asana, Inc. (0001477720) (Issuer)

    2/4/26 6:02:27 PM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    Director Anderson-Copperman Krista was granted 1,268 shares, increasing direct ownership by 2% to 65,788 units (SEC Form 4)

    4 - Asana, Inc. (0001477720) (Issuer)

    2/4/26 5:49:45 PM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    Director D'Angelo Adam was granted 731 shares, increasing direct ownership by 1% to 57,569 units (SEC Form 4)

    4 - Asana, Inc. (0001477720) (Issuer)

    2/4/26 5:49:00 PM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    $ASAN
    $JEQ
    $NVCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman & CEO Bentsur Ron bought $28,600 worth of shares (5,000 units at $5.72), increasing direct ownership by 0.14% to 3,525,924 units (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    11/6/25 8:01:11 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sanchez Juan bought $75,270 worth of shares (13,000 units at $5.79), increasing direct ownership by 20% to 78,150 units (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    11/6/25 8:00:38 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kaplan Matthew L. bought $64,240 worth of shares (11,000 units at $5.84), increasing direct ownership by 10% to 124,760 units (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    11/6/25 8:00:15 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASAN
    $JEQ
    $NVCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

    FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the year ended December 31, 2025 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "2025 was an eventful year for Nuvectis, with significant progress made in the NXP900 development program, laying the groundwork for multiple potential data readouts in 2026. Our Phase 1b monotherapy s

    2/11/26 7:30:00 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Asana to Announce Fourth Quarter and Fiscal Year 2026 Financial Results on Monday, March 2, 2026

    Asana, Inc. (NYSE:ASAN)(LTSE: ASAN), a leading work management platform for human + AI collaboration, announced today that it will release financial results for the fourth quarter and fiscal year 2026 on Monday, March 2, after the close of the U.S. markets. In conjunction with the announcement, the company will host a webcast on the same day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss the financial results. The live webcast and replay will be available on the Asana Investor Relations website at https://investors.asana.com. About Asana Asana is a leading work management platform for human and AI collaboration. Over 170,000 customers like Accenture, Amazon, Anthropic

    2/2/26 4:05:00 PM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

    Fort Lee, NJ, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the initiation of the Phase 1b study of NXP900 in combination with osimertinib in patients with EGFRmut+ NSCLC. NXP900, an oral small molecule drug candidate, is a potent inhibitor of the SRC and YES1kinases. The brand name for Osimertinib is Tagrisso®, marketed by Astra Zeneca. Tagrisso, a 3rd generation EGFR inhibitor is broadly used in patients with NSCLCmut+ as single agent or in combination with chemotherapy a

    12/17/25 7:00:00 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASAN
    $JEQ
    $NVCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Asana upgraded by Citigroup with a new price target

    Citigroup upgraded Asana from Neutral to Buy and set a new price target of $16.00

    1/15/26 8:27:19 AM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    BTIG Research initiated coverage on Asana

    BTIG Research initiated coverage of Asana with a rating of Neutral

    12/17/25 9:13:10 AM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    Asana upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded Asana from Sector Weight to Overweight and set a new price target of $18.00

    12/15/25 8:56:16 AM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    $ASAN
    $JEQ
    $NVCT
    SEC Filings

    View All

    SEC Form S-3 filed by Nuvectis Pharma Inc.

    S-3 - Nuvectis Pharma, Inc. (0001875558) (Filer)

    2/13/26 4:00:46 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

    2/11/26 8:10:37 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Nuvectis Pharma Inc.

    10-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

    2/11/26 8:02:44 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASAN
    $JEQ
    $NVCT
    Leadership Updates

    Live Leadership Updates

    View All

    Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors

    Fort Lee, NJ, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the appointment of Juan Sanchez, MD, to its Board of Directors. Dr. Sanchez is a seasoned biotech executive with expertise in industry, capital markets and medicine, having most recently served as Vice President of Corporate Communications and Investor Relations at Intra-Cellular Therapies, acquired by Johnson & Johnson in April 2025 for $14.6 billion. Ron Bentsur, Chairman and Chief Executive Officer of Nuvec

    9/25/25 8:00:00 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Asana Appoints Arnab Bose as Chief Product Officer

    Former Okta Executive to Lead Product Strategy in New Era of Human + AI Collaboration Asana, Inc. (NYSE:ASAN) (LTSE: ASAN), a leading enterprise work management platform for human + AI collaboration, today announced that Arnab Bose will join the company as Chief Product Officer, effective September 16, 2025. Bose will lead Asana's product strategy and innovation, as the company focuses on helping customers realize the productivity gains promised by AI and human teamwork. Bose joins Asana from Okta, where he served as Chief Product Officer, driving vision and strategy for both Workforce Identity and Customer Identity solutions—essentially building the orchestration layer that connects mi

    9/9/25 12:00:00 PM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    Asana Appoints Revenue Leader Marc Boroditsky to Board of Directors

    Boroditsky brings decades of experience scaling go-to-market strategies and revenue operations for Twilio, Cloudflare, as Asana charts new era as platform for AI and human coordination Asana, Inc. (NYSE:ASAN) (LTSE: ASAN), a leading enterprise work management platform, today announced the appointment of Marc Boroditsky to its Board of Directors. Mr. Boroditsky brings significant go-to-market expertise and a proven track record of scaling revenue organizations at high-growth, multi-billion dollar revenue SaaS companies, which will be instrumental to Asana's next stage of growth. "I'm excited to welcome Marc to our Board," said Dustin Moskovitz, CEO and co-founder of Asana. "Marc's extensiv

    4/17/25 4:05:00 PM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    $ASAN
    $JEQ
    $NVCT
    Financials

    Live finance-specific insights

    View All

    Asana Announces Third Quarter Fiscal 2026 Results

    Q3 revenue exceeded high-end of guidance Raises both high-end of FY26 revenue and non-GAAP operating income guidance ranges Announced AI Teammates: collaborative agents that understand the context of all work across the organization and deliver real business outcomes Asana, Inc. (NYSE:ASAN)(LTSE: ASAN), a leading work management platform for human and AI collaboration, today reported financial results for its third quarter fiscal 2026 ended October 31, 2025. "This was a solid quarter, with continued improvement in NRR and momentum with AI Studio," said Dan Rogers, Chief Executive Officer of Asana. "Our newly announced AI Teammates bring collaborative, context-aware agents with the right c

    12/2/25 4:05:00 PM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE DISTRIBUTION PAYMENT DETAILS

    PHILADELPHIA, Oct. 7, 2025 /PRNewswire/ -- The Aberdeen Investments U.S. Closed-End Funds (NYSE:JEQ), (the "Fund"), today announced that the Fund paid the distribution noted in the table below on October 7, 2025, on a per share basis to all shareholders of record as of September 29, 2025 (ex-dividend date September 29, 2025).    Ticker Exchange Fund Amount JEQ NYSE abrdn Japan Equity Fund, Inc. $0.6944 This distribution will be the final distribution paid from JEQ before the Fund's approved reorganization into abrdn Global Infrastructure Income Fund (NYSE:ASGI). Any sharehold

    10/7/25 4:17:00 PM ET
    $ASGI
    $JEQ
    Investment Managers
    Finance
    Air Freight/Delivery Services
    Consumer Discretionary

    ABRDN JAPAN EQUITY FUND, INC. (JEQ) ANNOUNCES FINAL ALL CASH DISTRIBUTION PAYMENT DETAILS

    PHILADELPHIA, Sept. 19, 2025 /PRNewswire/ -- abrdn Japan Equity Fund, Inc. (NYSE:JEQ), announced today that it will pay a $0.6944 per share cash distribution on October 7, 2025. This distribution represents the final allocation of long-term realized gains and net investment income. The distribution will be paid entirely in cash, with no option for dividend reinvestment. The details are as follows: Distribution Amount: $0.6944Record Date: September 29, 2025Ex-date: September 29, 2025Payment Date: October 7, 2025This distribution will be the final distribution paid from JEQ befo

    9/19/25 5:36:00 PM ET
    $ASGI
    $JEQ
    Investment Managers
    Finance
    Air Freight/Delivery Services
    Consumer Discretionary

    $ASAN
    $JEQ
    $NVCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by abrdn Japan Equity Fund Inc.

    SC 13G/A - ABRDN JAPAN EQUITY FUND, INC. (0000866095) (Subject)

    11/14/24 10:57:19 AM ET
    $JEQ
    Air Freight/Delivery Services
    Consumer Discretionary

    SEC Form SC 13G filed by Asana Inc.

    SC 13G - Asana, Inc. (0001477720) (Subject)

    11/13/24 12:33:25 PM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by Nuvectis Pharma Inc.

    SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)

    11/5/24 10:55:09 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care